These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 18095224)

  • 1. Optimizing use of colistin and polymyxin B in the critically ill.
    Nation RL; Li J
    Semin Respir Crit Care Med; 2007 Dec; 28(6):604-14. PubMed ID: 18095224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Shedding light on the use of colistin: still gaps to be filled].
    Luque S; Grau S; Berenguer N; Horcajada JP; Sorlí L; Montero MM; Salas E
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):287-96. PubMed ID: 21440335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymyxin B: similarities to and differences from colistin (polymyxin E).
    Kwa A; Kasiakou SK; Tam VH; Falagas ME
    Expert Rev Anti Infect Ther; 2007 Oct; 5(5):811-21. PubMed ID: 17914915
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Colistin and polymyxin B in critical care.
    Michalopoulos A; Falagas ME
    Crit Care Clin; 2008 Apr; 24(2):377-91, x. PubMed ID: 18361952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review.
    Zavascki AP; Goldani LZ; Li J; Nation RL
    J Antimicrob Chemother; 2007 Dec; 60(6):1206-15. PubMed ID: 17878146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in pharmacokinetics and pharmacodynamics of colistimethate sodium (CMS) and colistin between three different CMS dosage regimens in a critically ill patient infected by a multidrug-resistant Acinetobacter baumannii.
    Luque S; Grau S; Valle M; Sorlí L; Horcajada JP; Segura C; Alvarez-Lerma F
    Int J Antimicrob Agents; 2013 Aug; 42(2):178-81. PubMed ID: 23769664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics/pharmacodynamics of colistin and polymyxin B: are we there yet?
    Tran TB; Velkov T; Nation RL; Forrest A; Tsuji BT; Bergen PJ; Li J
    Int J Antimicrob Agents; 2016 Dec; 48(6):592-597. PubMed ID: 27793510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polymyxins for the treatment of extensively-drug-resistant Gram-negative bacteria: from pharmacokinetics to bedside.
    Zavascki AP
    Expert Rev Anti Infect Ther; 2014 May; 12(5):531-3. PubMed ID: 24666285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of susceptibility testing methods for polymyxin.
    Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC
    Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic evaluation of colistin sodium.
    Michalopoulos AS; Karatza DC; Gregorakos L
    Expert Opin Drug Metab Toxicol; 2011 Feb; 7(2):245-55. PubMed ID: 21128824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients.
    Kontopidou F; Plachouras D; Papadomichelakis E; Koukos G; Galani I; Poulakou G; Dimopoulos G; Antoniadou A; Armaganidis A; Giamarellou H
    Clin Microbiol Infect; 2011 Nov; 17(11):E9-E11. PubMed ID: 21939468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains.
    Alipour M; Halwani M; Omri A; Suntres ZE
    Int J Pharm; 2008 May; 355(1-2):293-8. PubMed ID: 18164881
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravenous polymyxin B in critically ill patients.
    Zavascki AP; Goldani LZ; Cao G; Superti SV; Lutz L; Barth AL; Ramos F; Boniatti MM; Nation RL; Li J
    Clin Infect Dis; 2008 Nov; 47(10):1298-304. PubMed ID: 18840079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections.
    Falagas ME; Kasiakou SK
    Clin Infect Dis; 2005 May; 40(9):1333-41. PubMed ID: 15825037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of 'old' polymyxins: what is new?
    Bergen PJ; Landersdorfer CB; Zhang J; Zhao M; Lee HJ; Nation RL; Li J
    Diagn Microbiol Infect Dis; 2012 Nov; 74(3):213-23. PubMed ID: 22959816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New information about the polymyxin/colistin class of antibiotics.
    Molina J; Cordero E; Pachón J
    Expert Opin Pharmacother; 2009 Dec; 10(17):2811-28. PubMed ID: 19929704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC; Reis AO; Jones RN
    J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of infections caused by Gram-negative pathogens: current status on the pharmacokinetics/pharmacodynamics of parenteral and inhaled polymyxins in patients.
    Lin YW; Aye SM; Rao G; Zhou QT; Chan HK; Li J
    Int J Antimicrob Agents; 2020 Dec; 56(6):106199. PubMed ID: 33075510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Polymyxins and their novel derivatives.
    Vaara M
    Curr Opin Microbiol; 2010 Oct; 13(5):574-81. PubMed ID: 20869908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. When to include polymyxins in the empirical antibiotic regimen in critically ill patients with fever? A decision analysis approach.
    Falagas ME; Rafailidis PI
    Shock; 2007 Jun; 27(6):605-9. PubMed ID: 17505298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.